By Christopher Kuo

Shares of Corbus Pharmaceuticals dropped after the biotechnology company reported data from its clinical study of a tumor treatment that showed adverse events among some patients.

The stock slid 31%, to $7.81, midday Tuesday and is down about 4% year to date.

The company, which focuses on treatments for cancer and obesity, on Tuesday reported data from its Phase 1/2 clinical study of CRB-701, an antibody-drug conjugate that targets a protein in certain solid tumors.

The company said Grade 3 treatment-related adverse events were reported in 19.2% of patients and Grade 4 adverse events--which are life-threatening or disabling--were reported in 0.9% of patients.

Corbus Pharmaceuticals said CRB-701 continued to be safe and well tolerated. The company is on track to start a registrational study of CRB-701 in the summer of 2026.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 26, 2026 14:59 ET (18:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.